Moving beyond the topic, Companion Diagnostics in Targeted Treatment, the panel took on the unregulated nature of testing in the wake of the June 2013 US Supreme Court ruling against Myriad Genetics, which ended the company's BRCA testing monopoly.
Michael A. Kolodziej, MD
Advertisement
Articles by Michael A. Kolodziej, MD
A lively discussion on Foundation Medicine's approach to creating genomic profiles.
Advertisement
Latest Updated Articles
- Grappling With the Fallout of Genetic Testing, in Oncology and Beyond
Published: January 29th 2014 | Updated:
- Next-Generation Sequencing in Oncology: Are We Ready for Prime Time?
Published: January 29th 2014 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer
2
Medicare State Rankings Reveal Stark Differences in Access, Quality, and Affordability
3
First-Line Zongertinib Yields Strong Responses in Patients With Advanced HER2-Mutant NSCLC
4
Real-World Data Show Preventive Nirsevimab Reduces Infant RSV Hospitalizations
5
